Drug Trial Radar · NCT00633347
Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation
Last checked: Nov 19, 2026Latest source record: Feb 15, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
570
Actual
Start
Jan 2007
Primary completion
Oct 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- Instituto Valenciano de Infertilidad, IVI VALENCIAAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 12, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 44 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Oocyte donation is a well established procedure in assisted reproduction treatments (ART). It is demonstrated that the use of hormonal substitution therapy, for the synchronization of the cycles between the recipients and the donors, provides good results, similar to the ones obtained with the natural cycle. In the patients - recipients with preserved ovarian function, the recipient's natural cycle is annulled, thus preventing the spontaneous Luteinizing Hormone surge. Simultaneously and while waiting for the suitable donor, her endometrium is prepared. When the donation occurs and fertilization with the husband sperm takes place, her cycle is stimulated again in order to synchronize her window of implantation with the donor's ovulation. Two different medications are commonly used to inhibit spontaneous ovulation: either GnRHa agonist or GnRH antagonists. The present study consists of the comparison between the single dose GnRH agonist (Decapeptyl 3,75 IM) and the 7 day dosage of GnRH antagonist (Cetrotide 0,25 mg). The administration of GnRHa is used fundamentally as a long liberation formulation, administered in a single intramuscular injection (IM), which is more practical in terms of use. Nevertheless, the unnecessary persistence and the potentially unfavorable action of GnRHa during the luteal phase and early gestation have questioned its use. The recovery of the Hypophysarian function begins only 8 weeks after the single injection of long liberation of triptorelina 3.75 mg. The GnRH antagonist (Cetrotide 0,25 mg) makes the hypofisary inhibition shorter than with the analogues and can prepare similar endometrium characteristics as a natural cycle. The recipients will be assigned randomly to a group of treatment or another.
Conditions
- Infertility
Interventions
Antagonist GnRH CetrotideDrug
Cetrotide 0.25 mg. daily/ 7 days
Agonist GnRH Acetate TriptorelineDrug
Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- clinical pregnancy rateTime frame: 1 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
IVI Valencia
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.